HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Brain tumor and Gliadel wafer treatment.

Abstract
Glioblastoma is a rapidly progressive and extremely fatal form of brain tumor with poor prognosis. It is the most common type of primary brain tumor. Even with the most aggressive conventional treatment that comprises surgery followed by radiotherapy and chemotherapy, most patients die within a year of diagnosis. Developments in molecular and cell biology have led to better understanding of tumor development, leading to novel treatment strategies including biological therapy and immunotherapy to combat the deadly disease. Targeted drug delivery strategies to circumvent the blood-brain barrier have shown efficiency in clinical trials. Gliadel wafer is a new approach to the treatment of glioblastoma, which involves controlled release delivery of carmustine from biodegradable polymer wafers. It has shown promising results and provides a silver lining for glioblastoma patients.
AuthorsM Panigrahi, P K Das, P M Parikh
JournalIndian journal of cancer (Indian J Cancer) 2011 Jan-Mar Vol. 48 Issue 1 Pg. 11-7 ISSN: 1998-4774 [Electronic] India
PMID21330749 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Delayed-Action Preparations
  • Carmustine
Topics
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Brain Neoplasms (drug therapy)
  • Carmustine (therapeutic use)
  • Delayed-Action Preparations
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: